David N Alexander MD
Neurorehabilitation, Vascular Neurology
Professor Emeritus, Department of Neurology, Geffen School of Medicine at UCLA Inaugural Susan and David Wilstein Endowed Chair in Rehabilitation Medicine 2016-2021 & Inaugural Medical Director, California Rehabilitation Institute, 2015-2020
Join to View Full Profile
Reed Neurological Research Center710 Westwood Plaza, C-239Los Angeles, CA 90095
Phone+1 310-825-2400
Fax+1 310-825-2400
Dr. Alexander is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Columbia Campus)Residency, Neurology, 1981 - 1983
Boston University Medical CenterInternship, Internal Medicine, 1979 - 1980
University of Minnesota Medical SchoolClass of 1979
Amherst CollegeBA, Neuroscience, 1975
Certifications & Licensure
NY State Medical License 1981 - Present
CA State Medical License 1983 - 2026
American Board of Physical Medicine and Rehabilitation Spinal Cord Injury Medicine
American Board of Psychiatry and Neurology Neurology- American Board of Psychiatry and Neurology Vascular Neurology
Awards, Honors, & Recognition
- Best Doctors in America 2009-2015
- Super Doctor SuperDoctors.com
Publications & Presentations
PubMed
- 3 citationsDextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial.Richard D. Zorowitz, David N. Alexander, Andrea E. Formella, Fred Ledon, Charles S. Davis
PM & R. 2019-01-01 - 2 citationsErratum to: PRISM II: An open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic ...Flora M. Hammond, David N. Alexander, Andrew J. Cutler, Stephen D'Amico, Rachelle S. Doody
BMC Neurology. 2016-09-02 - 10 citationsPRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.Flora M Hammond, David N Alexander, Andrew J Cutler, Stephen D'Amico, Rachelle S Doody
BMC Neurology. 2016-06-09
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
